RocRock Biotech Accepts an Interview with

RocRock Biotech team, in the field of cell therapy, is currently at the forefront of pipelines "combating" solid tumors such as breast cancer, pancreatic cancer, and lung cancer, as well as internationally collaborating with Armenia to tackle rare diseases like Mediterranean fever. The goal is to fulfill the long-cherished wish of "improving drug efficacy" and "reducing prices."

RocRock Biotech is a clinical-stage cell therapy company focusing on the research of macrophage-based drug treatments for cancer. In 2023, RocRock Biotech, in collaboration with the Affiliated Hospital of Xuzhou Medical University, initiated an Investigator Initiated Trial (IIT) for the RR-M01 pipeline. The trial has completed the drug administration assessment for multiple subjects, confirming that the RR-M01 pipeline has good drug safety and efficacy, bringing new hope for the treatment of malignant solid tumors, especially recurrent and refractory ovarian cancer. The RR-M01 pipeline is expected to complete the enrollment and drug administration for the last patient in October 2024. At the same time, the indications for the RR-M01 pipeline have been further expanded to all solid tumors that are HER2-positive or have low expression, and it obtained ethical approval from the Affiliated Hospital of Xuzhou Medical University in early March 2024. Nearly half of the subjects have been administered the drug, and the plan for 2024 is to complete the recruitment of 20 patients. Additionally, clinical trials targeting pancreatic cancer, prostate cancer, and small cell lung cancer are also progressing smoothly.